This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Xencor’s 8K filing here.
About Xencor
Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.
Further Reading
- Five stocks we like better than Xencor
- Financial Services Stocks Investing
- Upstart’s Uptrend Is Just Getting Started: Its Time to Load Up
- Trading Stocks: RSI and Why it’s Useful
- Archer Aviation Lands BlackRock Investment—What’s Next for ACHR?
- Following Congress Stock Trades
- Buffett Buys More Occidental Petroleum—Sticking to His Playbook
